Top-five pharmaceutical company expands partnership with Aptamer for multi-target Optimer® development program
Aptamer Group plc, the developer of next-generation synthetic binders for the life sciences industry, today announced a new contract valued at up to £617,000 with a top-five pharmaceutical company. The expanded partnership will focus on developing Optimer® binders against three therapeutic targets to support drug validation and potential clinical trial applications. New multi-target development…
View On WordPress
















